About Us

Our Story

Committed to the Ophthalmic Excellence

Aseel Bedan is a consultant ophthalmic surgeon at Ashford and St Peter’s Hospitals NHS Foundation Trust. She works at BMI Hendon Hospital and BMI Sudbury and Willesden eye clinic as well.

Upon moving to the UK and furthering her learning in the medical profession, Ms. Bedan received a two year fellowship in medical retina and research from Western Eye Hospital from 2015 – 2017. She gained her degree as a Fellow of Royal College of Surgeons in Glasgow in 2011, she was trained in the Republic of Ireland and obtained her degree as Member of Royal College of Surgeons in Ireland MRCSI in 2014, European Board of Ophthalmology EBO in 2013, International Council of Ophthalmology ICO in 2009. Back in Iraq she was qualified as a consultant ophthalmologist with a degree from Council of Arab Board of Ophthalmology CAB ophth. in 2004. She had her primary medical qualification MBChB from the University of Baghdad in 1993.

Upon her career, she worked in Western Eye Hospital (Imperial College Hospital), Maidstone & Tunbridge Wells NHS Trust in Kent, Royal Victoria Eye & Ear Hospital in Dublin, Cork University Hospital, and University Hospital Limerick.

Our Values

Our Work is Heavily Shaped by our Core Values

01.

Professional Membership

  • General Medical Council – Number 7095890, specialist registration.
  • European Society of Cataract and Refractive Surgeons – Member
  • European Society of Retina Specialists – Member
  • American Academy of Ophthalmology – Member
  • The Association for Research in Vision and Ophthalmology – Member
02.

Areas of interest

  • Her special interests include routine/ complex cataract surgery.
  • Medical retina diseases including age-related macular degeneration with OCT, FFA, ICG, intravitreal injection therapy with Anti-VEGF and Dexamethasone.
  • Diabetic eye disease including Argon & Micro-pulse laser treatment, anti-VEGF & steroid injection with elyea, lucentis, ozurdex and iluvien.
  • Retinal vein occlusion management with intravitreal injections and laser.
  • Central serous retinopathy treatment.
  • General ophthalmology.

 

03.

Publications & presentations

  1. Fluocinolone Acetonide Intravitreal Implant 0.19 mg: A Review in Diabetic Macular Oedema. A poster presented in Euretina 2018.
  2. Untargeted large spot half-fluence photodynamic therapy for chronic central serous chorioretinopathy, a poster presented in ARVO 2018.
  3. Three Years Out-come of Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Oedema in Maidstone Hospital, UK. A poster presented in Euretina winter meeting 2018.
  4. Advances in interventions for chronic and recurrent central serous chorioretinopath (CSCR), a poster presented in Euretina winter meeting 2018.
  5. Three years outcome of fluocinolone acetonide intravitreal implant for diabetic macular oedema in Maidstone Hospital, UK. A poster presented in Euretina winter meeting 2018.
  6. Long-term outcomes of photodynamic therapy in chronic central serous retinopathy. A poster presented in Euretina winter meeting 2018.
  7. Sub threshold laser Treatment for Central Serous Chororioretinopathy, a poster presented in Euretina 2017.
  8. Chronic central serous chorioretinopathy treated with Spironolactone, a poster presented in Euretina 2017.
  9. Three-year outcomes of a Treat-and-Extend regimen of intravitreal Aflibercept for wet ARMD at the Western Eye Hospital, a poster presented in Euretina 2017.
  10. Progression and Incidence of Geographic Atrophy in Patients with Wet Age-Related Macular Degeneration undergoing AntiVEGF Therapy, a poster presented in ARVO 2017.
  11. Audit of wet AMD patients treated with IV Ranibizumab over 6-12 months, a poster resented in Ophthalmologica Belgica Congress 2017.
  12. Dual Branch Retinal Vein Occlusion in one eye-case presentation, a poster resented in Ophthalmologica Belgica Congress 2017.
  13. Audit on treatment of macular oedema in CRVO with anti-VEGF at the WEH, a poster presented in the Retinal Medical Audit Meeting, London 2016.
  14. Sub threshold Laser Treatment for Central Serous Chorioretinopathy, presented in the Imperial College Research Group (ICORG) Annual Research Medal and Alumni Event 2016.
  15. Central Retinal Artery Occlusion, presentation in the Western Eye Hospital 2016
  16. Diabetic Macular Oedema, presentation in the Western Eye Hospital 2016.
  17. Orbital lymphoma case study, presented in the Irish College of Ophthalmology ICO annual meeting, Dublin Dec. 2014.
  18. Serpiginous Choroiditis Case study in RAMI meeting, Ireland March 2014.
  19. Use of triple procedure surgery for the management of recurrent crystalline keratopathy RAMI meeting, Ireland March 2014.
  20. “Aaudit of fundus fluorecein angiography over a six months period at Cork University Hospital” submitted in RAMI meeting Ireland December 2012.
  21. “Ocular Findings of Down’s Syndrome in Iraq” Published in the Journal Faculty of Medicine Baghdad 2006; vol. 48, No.1.
04.

Published Articles

  1. Progression and Incidence of Geographic Atrophy in Patients with Wet Age-Related Macular Degeneration undergoing Anti- VEGF Therapy | SciTechnol
  2.  Three-year Outcomes of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Wet ARMD at the Western Eye Hospital | SciTechnol
  3. “Ocular Findings of Down’s Syndrome in Iraq” Published in the Journal Faculty of Medicine Baghdad 2006; vol. 48, No.1.
  4. Subthreshold Micropulse Yellow Laser Treatment for Central Serous Chororioretinopathy, submitted and accepted.
  5. Four articles published in the periodic military journal of the Dubai Police Headquarters (Alamin):
    a- “The effect of Diabetes on the eye”, vol. 428, September 2010.
    b-     “Children & prescribed glasses”, vol. 417, October 2009.
    c- “Glaucoma”, vol. 416, September 2009.
    d- “Viral eye infection”, vol.415, August 2009.
05.

Researches

co-author in:

  1. LEAVO study 10/2016. Aim of research:To monitor the response of CMO in CRVO to various types of anti VEGF treatment. Conclusions/Actions: Double-blind randomised controlled trial comparing the clinical and cost effectiveness of intravitreal therapy with LUCENTIS vs AVASTIN vs EYLEA for Macular Oedema due to CRVO.
  2.  SAFARI date 12/2016. Aim of research: evaluating the efficacy and safety of switching from intravitreal Aflibercept to Ranibizumab.
    Conclusions/Actions: Prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration, evaluating the efficacy and safety of switching from intravitreal Aflibercept to Ranibizumab.
  3. DRAKO Study, date 12/2016. Aim of research: Assess the effectiveness of antivitreal aflibercept in patients with visual impairment due to diabetic macular oedema.
    Conclusions/Actions: An observational study to assess the effectiveness of antivitreal aflibercept in routine clinical practice in patients with visual impairment due to diabetic macular oedema
  4. 16-Intravitreal triamcinolone injection versus focal laser treatment for treatment of resistant diabetic macular oedema presented in the Royal Victoria Eye and Ear Hospital, Dublin 2015
06.

Teaching Experience

  1. Participating in teaching & training of undergraduate students in Ashford & St Peter’s Hospitals, WEH London & Maidstone & Tunbridge Wells NHS Trust.
  2. Special Lecturer/Registrar in University College Dublin 2014-2015.
  3. Gave many clinical sessions to undergraduate students in Cork University Hospital.
  4. Participate in the oral final exam for the undergraduates of University College Cork in 2012.
  5. Did a lecture about Glaucoma for ophthalmic nurses in Ibn al Haitham Teaching Eye Hospital, Baghdad- Iraq in 2005.
  6. Clinical lectures to undergraduate students of Baghdad University during my work as a senior registrar in 2005-2006.
  7. Public lecture to patients of Dubai Police Polyclinic about Glaucoma in 2009. 
Book an Appoinment
Call Today

074 7018 5991

Secretary Moe Shlash

074 70185 991

WhatsApp

074 7018 5991

Email

infol@aseel-bedan.com